info@flamel.com
Home | Company | Technologies and Products | Investor Relations | Press Releases | Contact
 
2008
2007
2006
2005
2004
2003
2002
2001
Archives


Latest News

April 25, 2008
Flamel Technologies Presents Results of Two Week Study of Interferon Alpha XL at the European Association for the Study of the Liver

March 4, 2008
Flamel Technologies Fourth Quarter and Year End 2007 Earnings Results Conference Call,
8:30 EST

March 3, 2008
Flamel Technologies Announces Fourth Quarter and Year-End Results; Fourth quarter includes strong clinical results; new agreements; and cash maintained at $41 million

March 3, 2008
Flamel Technologies Announces Nomination of Dr. Frank Fildes to Board of Directors; Flamel Technologies also announces departure of Michel Finance and appointment of Sian Crouzet


Medusa®

A Versatile Nano Carrier for the Delivery of Native Proteins

Medusa®, a self-assembled poly-aminoacid nanoparticles system, is a versatile protein carrier for the development of novel and second-generation long-acting native protein drugs. more info

Also available:
"Novel sustained release formulation of IFN-alfa-2b-XL, improves tolerability and demonstrates potent viral load reduction in a phase I/II HCV clinical trial" click here

"Novel Sustained Release Formulation of IL-2 Improves Pharmacokinetics Performance
and Demonstrates Potent Activation of Immunological Cell Line" click here

Micropump® Technologies
From Pediatric to Geriatric Uses

Controlled-release systems permitting either extended (Micropump® I) or both delayed and extended (Micropump® II) delivery of small molecule drugs.

more info


December 21, 2004
Flamel Technologies Announces Completion of a Commercial Supply Agreement with Glaxo-Smith Kline for Drug in Phase III Trials

December 17, 2004
Flamel Technologies Announces Initiation of Phase I/II trial of Medusa Formulation of Long-Acting Interferon-alpha for Hepatitis B and Hepatitis C Treatment

December 8, 2004
Flamel Technologies Announces Initiation of Phase I/II trial of Medusa Formulation of Long-Acting Interleukin-2 for Cancer Treatment

October 28, 2004
Flamel Technologies Announces Third Quarter Results
Transcript of the conference call

October 25, 2004
Flamel Technologies Announces Projected Release Date of Third Quarter, Conference Call

September 16, 2004
Flamel Technologies Announces the License of Flamel's Micropump Technology to TAP Pharmaceutical Products Inc. for Lansoprazole, Conference Call
Webcast

September 16, 2004
Flamel Technologies Announces Initiation of Phase III trial for Micropump Formulation of a GlaxoSmithKline Product, Conference Call
Webcast

September 16, 2004
Flamel Technologies Announces Termination of License Agreement for Long-Acting Insulin, Conference Call
Webcast

July 29, 2004
Flamel Technologies Announces Second Quarter Revenues of $9.0 Million, Cash at $101 Million
Webcast for Q2 2004
Replay of the CC: (800) 642-1687 (US) or (706) 645-9291 (international)
conference ID: 8771969
Transcript of the conference call

July 26, 2004
Flamel Technologies Announces Projected Release Date of Second Quarter Results, Conference Call

July 1, 2004
Flamel Technologies Announces Selection of a Flamel Micropump Formulation to Progress to Phase III Clinical Trials

April 29, 2004
Flamel Technologies Announces First Quarter Revenues of $14.4 Million, Earnings of $0.20 Per Share

April 26, 2004
Flamel Technologies Announces Projected Release Date of First Quarter Results, Conference Call

April 1, 2004
Flamel Technologies announces receipt of $5 million milestone payment from Bristol-Myers Squibb Company

March 11, 2004
Flamel Technologies announces fourth quarter and year end 2003 results

March 4, 2004
Flamel Technologies announces projected release date of fourth quarter and year end results, conference call

January 5, 2004
Flamel Technologies announces receipt of milestone payment from GlaxoSmithKline

Micropump® and Medusa® are registered trademarks of Flamel Technologies S.A.
Copyrights © 2006 Flamel Technologies S.A. All rights reserved